Ramachandran Anassuya, Marshall Elaine S, Love Donald R, Baguley Bruce C, Shelling Andrew N
Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.
Cancer Lett. 2009 Nov 28;285(2):157-65. doi: 10.1016/j.canlet.2009.05.010. Epub 2009 Jun 2.
Although activin is a major cytokine produced by the ovary, its role in epithelial ovarian cancer is poorly defined. Here, we demonstrate a novel role for activin as a growth inhibitor of some (8/16) epithelial ovarian cancer cell lines. Unresponsive cell lines displayed transcriptional downregulation of the activin receptors ACTRIIA and ACTRIB, suggesting resistance to activin signalling. In response to activin, growth inhibited cell lines demonstrated activation of the canonical SMAD2/3/4, transcriptional induction of the CDK inhibitor p15INK4B, suppression of C-MYC levels and a G1 phase cell cycle arrest. Thus, activin is a potent inhibitor of proliferation of some epithelial ovarian cancer cell lines and its role in the pathogenesis of this disease needs to be re-evaluated.
尽管激活素是卵巢产生的一种主要细胞因子,但其在上皮性卵巢癌中的作用仍不清楚。在此,我们证明了激活素作为某些(8/16)上皮性卵巢癌细胞系生长抑制剂的新作用。无反应的细胞系显示激活素受体ACTRIIA和ACTRIB的转录下调,提示对激活素信号传导有抗性。响应激活素时,生长受抑制的细胞系表现出经典的SMAD2/3/4激活、CDK抑制剂p15INK4B的转录诱导、C-MYC水平的抑制以及G1期细胞周期停滞。因此,激活素是某些上皮性卵巢癌细胞系增殖的有效抑制剂,其在该疾病发病机制中的作用需要重新评估。